Bicyclic peptide ligands specific for MT1-MMP
The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of membrane type 1 metalloprotease (MT1-MMP). The invention also describes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups which have utility in imaging and targeted cancer therapy.
1. A method for treating cancer in a patient, comprising administering to the patient a peptide ligand specific for MT1-MMP (membrane type 1 metalloprotease), or a pharmaceutically acceptable salt thereof, wherein the peptide ligand comprises a polypeptide comprising at least three cysteine residues, separated by at least two loop sequences, and a molecular scaffold which forms covalent bonds with the cysteine residues of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold, wherein the peptide ligand comprises the amino acid sequence:
(SEQ ID NO: 1)
-C i -X 1 -U/O 2 -X 3 -X 4 -G 5 -C ii -E 6 -D 7 -F 8 -Y 9 -X 10 -X 11 -C iii -;
wherein:
C i , C ii and C iii represent first, second and third cysteine residues, respectively;
each of X 1 , X 3 , X 4 , X 10 and X 11 represents any natural amino acid residue;
U/O 2 represents that position 2 of the loop sequence between C i and C ii is U or O;
U represents a polar, uncharged amino acid residue selected from the group consisting of N, C, Q, M, S and T; and
O represents a non-polar aliphatic amino acid residue selected from the group consisting of G, A, I, L, P and V, and
wherein the cancer is selected from the group consisting of a tumor of epithelial origin, a tumor of the central or peripheral nervous system, and a fibrosarcoma.
2. The method according to claim 1 , wherein X 1 is selected from the group consisting of Y, M, F and V.
3. The method according to claim 1 , wherein U/O 2 represents N or G.
4. The method according to claim 1 , wherein X 3 is U or Z, wherein U is selected from the group consisting of N, C, Q, M, S and T, and Z is selected from the group consisting of D and E; or
wherein U is Q and Z is E.
5. The method according to claim 1 , wherein X 4 is selected from the group consisting of F, W and Y.
6. The method according to claim 1 , wherein
X 10 is selected from the group consisting of D and E; and
X 11 is selected from the group consisting of G, A, I, L, P and V.
7. The method according to claim 4 , wherein the amino acid sequence SEQ ID NO: 1 is selected from the group consisting of:
(SEQ ID NO: 6)
-C i -Y/M/F/V-U/O-J-G-C ii -E-D-F-Y-Z-O-C iii -,
(SEQ ID NO: 7)
-C i -Y/M/F/V-N/G-E/Q-F-G-C ii -E-D-F-Y-D-I-C iii -,
(SEQ ID NO: 8)
-C i -Y/M/F-N/G-E/Q-F-G-C ii -E-D-F-Y-D-I-C iii -,
(SEQ ID NO: 9)
-C i -Y/M-N-E/Q-F-G-C ii -E-D-F-Y-D-I-C iii -,
and
(SEQ ID NO: 2)
-C i -Y-N-E-F-G-C ii -E-D-F-Y-D-I-C iii -.
8. The method according to claim 1 , wherein the amino acid sequence SEQ ID NO: 1 is selected from the group consisting of:
(SEQ ID NO: 2)
-C i -Y-N-E-F-G-C ii -E-D-F-Y-D-I-C iii -;
(SEQ ID NO: 10)
-C i -M-N-Q-F-G-C ii -E-D-F-Y-D-I-C iii -;
(SEQ ID NO: 11)
-C i -F-G-E-F-G-C ii -E-D-F-Y-D-I-C iii -;
(SEQ ID NO: 12)
-C i -V-N-E-F-G-C ii -E-D-F-Y-D-I-C iii -;
(SEQ ID NO: 13)
-C i -F-N-E-F-G-C ii -E-D-F-Y-D-I-C iii -;
(SEQ ID NO: 14)
-C i -Y-N-E-Y-G-C ii -E-D-F-Y-D-I-C iii -;
and
(SEQ ID NO: 15)
-C i -Y-N-E-W-G-C ii -E-D-F-Y-D-I-C iii -.
9. The method according to claim 1 , wherein the peptide ligand is a free acid or a sodium, potassium, calcium, or ammonium salt.
10. The method according to claim 1 , wherein the peptide ligand is a high affinity binder of the human, mouse and dog MT1-MMP hemopexin domain, wherein the peptide ligand does not cross-react with MMP-1, MMP-2, MMP-15 and MMP-16.
11. The method according to claim 1 , wherein the tumor of epithelial origin is selected from the group consisting of a carcinoma of the bladder and urinary tract, breast, gastrointestinal tract, liver, gall bladder and biliary system, exocrine pancreas, kidney, lung, head and neck, ovary, fallopian tubes, peritoneum, vagina, vulva, penis, cervix, myometrium, endometrium, thyroid, adrenal, prostate, skin and adnexae.
12. The method according to claim 11 , wherein the carcinoma of the lung is selected from the group consisting of an adenocarcinoma, a small cell lung carcinoma, a non-small cell lung carcinoma, a bronchioalveolar carcinoma and a mesothelioma.
13. The method according to claim 12 , wherein the carcinoma of the lung is a non-small cell lung carcinoma.
14. The method according to claim 11 , wherein the tumor of epithelial origin is selected from the group consisting of a carcinoma of the bladder and urinary tract, breast, gastrointestinal tract, liver, exocrine pancreas, kidney, lung, head and neck, ovary, prostate, and skin.
15. The method according to claim 1 , wherein the cancer is a tumor of the central or peripheral nervous system.
16. The method according to claim 1 , wherein the cancer is a fibrosarcoma.
17. A method for treating cancer in a patient, comprising administering to the patient a drug conjugate BT17BDC-18, which is of formula (IV):
wherein:
Toxin is the cytotoxic agent DM1;
Bicycle represents a peptide ligand comprising:
a polypeptide of the amino acid sequence:
(B-Ala)-Sar10-AC(D-Ala)NE(1NaI)(D-Ala)CEDFYD(tBuGly)C (SEQ ID NO: 5); and
a molecular scaffold which is TBMB (1,3,5-tris(bromomethyl)benzene), which forms covalent bonds with the cysteine residues of the polypeptide yielding a tri-substituted 1,3,5-trismethylbenzene structure;
R 3 represents methyl, and R 1 , R 2 and R 4 each represent hydrogen;
m represents 1; and
n represents 1,
or a pharmaceutically acceptable salt thereof, and
wherein the cancer is selected from the group consisting of a tumor of epithelial origin, a tumor of the central or peripheral nervous system, and a fibrosarcoma.
18. The method according to claim 17 , wherein the peptide ligand is a free acid or a sodium, potassium, calcium, or ammonium salt.
19. The method according to claim 17 , wherein the tumor of epithelial origin is selected from the group consisting of a carcinoma of the bladder and urinary tract, breast, gastrointestinal tract, liver, gall bladder and biliary system, exocrine pancreas, kidney, lung, head and neck, ovary, fallopian tubes, peritoneum, vagina, vulva, penis, cervix, myometrium, endometrium, thyroid, adrenal, prostate, skin and adnexae.
20. The method according to claim 19 , wherein the carcinoma of the lung is selected from the group consisting of an adenocarcinoma, a small cell lung carcinoma, a non-small cell lung carcinoma, a bronchioalveolar carcinoma and a mesothelioma.
21. The method according to claim 20 , wherein the carcinoma of the lung is a non-small cell lung carcinoma.
22. The method according to claim 19 , wherein the tumor of epithelial origin is selected from the group consisting of a carcinoma of the bladder and urinary tract, breast, gastrointestinal tract, liver, exocrine pancreas, kidney, lung, head and neck, ovary, prostate, and skin.
23. The method according to claim 17 , wherein the cancer is a tumor of the central or peripheral nervous system.
24. The method according to claim 17 , wherein the cancer is a fibrosarcoma.